scholarly journals Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal

PLoS Medicine ◽  
2009 ◽  
Vol 6 (10) ◽  
pp. e1000173 ◽  
Author(s):  
Elena Losina ◽  
Hapsatou Touré ◽  
Lauren M. Uhler ◽  
Xavier Anglaret ◽  
A. David Paltiel ◽  
...  
2006 ◽  
Vol 355 (11) ◽  
pp. 1141-1153 ◽  
Author(s):  
Sue J. Goldie ◽  
Yazdan Yazdanpanah ◽  
Elena Losina ◽  
Milton C. Weinstein ◽  
Xavier Anglaret ◽  
...  

2019 ◽  
Vol 6 (7) ◽  
Author(s):  
Sophie Desmonde ◽  
Simone C Frank ◽  
Ashraf Coovadia ◽  
Désiré L Dahourou ◽  
Taige Hou ◽  
...  

Abstract Background The NEVEREST-3 (South Africa) and MONOD-ANRS-12206 (Côte d’Ivoire, Burkina Faso) randomized trials found that switching to efavirenz (EFV) in human immunodeficiency virus–infected children >3 years old who were virologically suppressed by ritonavir-boosted lopinavir (LPV/r) was noninferior to continuing o LPV/r. We evaluated the cost-effectiveness of this strategy using the Cost-Effectiveness of Preventing AIDS Complications–Pediatric model. Methods We examined 3 strategies in South African children aged ≥3 years who were virologically suppressed by LPV/r: (1) continued LPV/r, even in case of virologic failure, without second-line regimens; continued on LPV/r with second-line option after observed virologic failure; and preemptive switch to EFV-based antiretroviral therapy (ART), with return to LPV/r after observed virologic failure. We derived data on 24-week suppression (<1000 copies/mL) after a switch to EFV (98.4%) and the subsequent risk of virologic failure (LPV/r, 0.23%/mo; EFV, 0.15%/mo) from NEVEREST-3 data; we obtained ART costs (LPV/r, $6–$20/mo; EFV, $3–$6/mo) from published sources. We projected discounted life expectancy (LE) and lifetime costs per person. A secondary analysis used data from MONOD-ANRS-12206 in Côte d’Ivoire. Results Continued LPV/r led to the shortest LE (18.2 years) and the highest per-person lifetime cost ($19 470). LPV/r with second-line option increased LE (19.9 years) and decreased per-person lifetime costs($16 070). Switching led to the longest LE (20.4 years) and the lowest per-person lifetime cost ($15 240); this strategy was cost saving under plausible variations in key parameters. Using MONOD-ANRS-12206 data in Côte d’Ivoire, the Switch strategy remained cost saving only compared with continued LPV/r, but the LPV/r with second-line option strategy was cost-effective compared with switching. Conclusion For children ≥3 years old and virologically suppressed by LPV/r-based ART, preemptive switching to EFV can improve long-term clinical outcomes and be cost saving. Clinical Trials Registration NCT01127204


AIDS ◽  
2005 ◽  
Vol 19 (12) ◽  
pp. 1299-1308 ◽  
Author(s):  
Yazdan Yazdanpanah ◽  
Elena Losina ◽  
Xavier Anglaret ◽  
Sue J Goldie ◽  
Rochelle P Walensky ◽  
...  

2015 ◽  
Vol 55 (2) ◽  
pp. e83-e86 ◽  
Author(s):  
Komenan Kassi ◽  
Djokouehi Djeha ◽  
Ildevert P. Gbery ◽  
Kanga Kouame ◽  
Abdoulaye Sangaré

2017 ◽  
Vol 22 (4) ◽  
pp. 431-441 ◽  
Author(s):  
Margaret L. McNairy ◽  
Jules B. Bashi ◽  
Hannah Chung ◽  
Louise Wemin ◽  
Marie-Nicole Akpro Lorng ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Valentine Becquet ◽  
Marcellin Nouaman ◽  
Mélanie Plazy ◽  
Aline Agoua ◽  
Clémence Zébago ◽  
...  

Abstract Background Pre-exposure prophylaxis (PrEP) is recommended by the WHO for HIV prevention among female sex workers (FSWs). A study conducted in 2016–2017 in Côte d’Ivoire showed that if PrEP is acceptable, FSWs also have many uncovered sexual health needs. Based on this evidence, the ANRS 12381 PRINCESSE project was developed in collaboration with a community-based organization. The main objective is to develop, document, and analyze a comprehensive sexual and reproductive healthcare package among FSWs in Côte d’Ivoire. Methods PRINCESSE is an open, single-arm interventional cohort of 500 FSWs in San Pedro (Côte d’Ivoire) and its surroundings. Recruitment started on November 26th, 2019 and is ongoing; the cohort is planned to last at least 30 months. The healthcare package (including HIV, hepatitis B, and sexually transmitted infection management, pregnancy screening, and contraception) is available both at mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and at a fixed clinic. Four waves of data collection were implemented: (i) clinical and safety data; (ii) socio-behavioral questionnaires; (iii) biological data; and (iv) in-depth interviews with female participants. Four additional waves of data collection are scheduled outside the cohort itself: (i) the medical and activity records of Aprosam for the PRINCESSE participants; (ii) the medical records of HIV+ FSW patients not participating in the PRINCESSE cohort, and routinely examined by Aprosam; (iii) in-depth interviews with key informants in the FSW community; and (iv) in-depth interviews with PRINCESSE follow-up actors. Discussion The PRINCESSE project is one of the first interventions offering HIV oral PrEP as part of a more global sexual healthcare package targeting both HIV- and HIV+ women. Second, STIs and viral hepatitis B care were offered to all participants, regardless of their willingness to use PrEP. Another innovation is the implementation of mobile clinics for chronic/quarterly care. In terms of research, PRINCESSE is a comprehensive, interdisciplinary project combining clinical, biological, epidemiological, and social specific objectives and outcomes to document the operational challenges of a multidisease program in real-life conditions. Trial registration The PRINCESSE project was registered on the Clinicaltrial.gov website (NCT03985085) on June 13, 2019.


PLoS ONE ◽  
2021 ◽  
Vol 16 (12) ◽  
pp. e0260530
Author(s):  
Tamsin K. Phillips ◽  
Halli Olsen ◽  
Chloe A. Teasdale ◽  
Amanda Geller ◽  
Mamorapeli Ts’oeu ◽  
...  

Transitions between services for continued antiretroviral treatment (ART) during and after pregnancy are a commonly overlooked aspect of the HIV care cascade, but ineffective transitions can lead to poor health outcomes for women and their children. In this qualitative study, we conducted interviews with 15 key stakeholders from Ministries of Health along with PEPFAR-supported and other in-country non-governmental organizations actively engaged in national programming for adult HIV care and prevention of mother-to-child-transmission of HIV (PMTCT) services in Côte d’Ivoire, Lesotho and Malawi. We aimed to understand perspectives regarding transitions into and out of PMTCT services for continued ART. Thematic analysis revealed that, although transitions of care are necessary and a potential point of loss from ART care in all three countries, there is a lack of clear guidance on transition approach and no formal way of monitoring transition between services. Several opportunities were identified to monitor and strengthen transitions of care for continued ART along the PMTCT cascade.


Sign in / Sign up

Export Citation Format

Share Document